Previous 10 | Next 10 |
2023-11-13 02:36:21 ET Japan ( NKY:IND ) +0.05% Japan PPI for October -0.4% m/m (expected 0.0%) and +0.8% y/y (expected +0.9%). China ( SHCOMP ) +0.25% . Hong Kong ( HSI ) +0.61% . India ( SENSEX ) -0.49% . Total passenger...
2023-11-10 02:53:35 ET Japan ( NKY:IND ) -0.24% . China ( SHCOMP ) -0.47%. China's vehicle sales continue thrive, New Energy Vehicles (NEV) sales rocketing by 33.5%. October vehicle sales were up 13.8% y/y (from September's +9.5%). Hong Kong&...
2023-11-09 03:10:08 ET Japan ( NKY:IND ) +1.49% . Japan's current account surplus surged to JPY 2,726.3 billion in September 2023 from JPY 853.08 billion in the same month a year earlier but less than market estimates of a gain of JPY 3,000.8 billion. The gauge for Japa...
2023-11-08 03:12:05 ET Japan ( NKY:IND ) -0.33% . The Reuters Tankan sentiment index for manufacturers in Japan rose to +6 in November 2023 from +4 in October, showing an improvement in business confidence for the first time since August. Reserve assets in Japan rose sl...
2023-11-08 02:32:12 ET CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Conference Call November 7, 2023 17:00 ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Conference C...
2023-11-07 16:41:31 ET More on CytomX Seeking Alpha’s Quant Rating on CytomX Historical earnings data for CytomX Financial information for CytomX For further details see: CytomX GAAP EPS of $0.04 beats by $0.21, revenue of $26.38M beats by $12.97M
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 (EpCAM-directed ADC) comprehensive preclinical profile presented at 14 th Annual World ADC Conference; IND filing on track for year-end - ...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
CytomX Therapeutics Inc. (CTMX) is expected to report $-0.17 for Q3 2023
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report third quarter financial results on Tuesday, November 7, 2023, after the close of...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...